DeepMed Research

LY-2456302

Generic Name: LY-2456302

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₇FN_₂O_₂

CAS Number: 1174130-61-0

Unique Ingredient Identifier: DE4G8X55F5

Background: Ly2456302 has been used in trials studying the health services research and basic science of Anxiety Disorders and Alcohol Dependence.

Clinical Trials

A Study in a Human Laboratory Model of Smoking Behavior

Phase 2

Completed

Conditions: Smoking

Interventions: Drug: CERC-501
Drug: Placebo

First Posted Date: 2015-12-29

Last Posted Date: 2025-04-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 71

Registration Number: NCT02641028

Locations: 🇺🇸
Vince and Associates, Overland Park, Kansas, United States
🇺🇸
University of Kentucky, Lexington, Kentucky, United States
🇺🇸
Columbia University, New York, New York, United States

Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a

Phase 2

Completed

Conditions: ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)

Interventions: Drug: CERC-501
Drug: placebo

First Posted Date: 2014-08-18

Last Posted Date: 2019-01-08

Lead Sponsor: Duke University

Target Recruit Count: 163

Registration Number: NCT02218736

Locations: 🇺🇸
CaseWestern Reserve University, Cleveland, Ohio, United States
🇺🇸
Andrew Goddard, MD, Indianapolis, Indiana, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

and more 3 locations

FASTMAS (Fast-Fail Trials in Mood and Anxiety Spectrum Disorders) Kappa Opioid Receptor Phase 1 Study

Phase 1

Withdrawn

Conditions: Anxiety Disorders

Interventions: Drug: LY2456302

First Posted Date: 2014-08-18

Last Posted Date: 2015-05-28

Lead Sponsor: Andrew Krystal

Registration Number: NCT02218775

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression

Phase 2

Terminated

Conditions: Treatment Resistant Depression

Interventions: Drug: CERC-501
Drug: Placebo

First Posted Date: 2013-08-01

Last Posted Date: 2017-07-02

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 8

Registration Number: NCT01913535

Locations: 🇺🇸
University of Kansas, Wichita, Kansas, United States
🇺🇸
Rush University, Chicago, Illinois, United States
🇺🇸
Temple University, Philadelphia, Pennsylvania, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy